REGULATORY
FDA briefing addresses BPC-157 in 503A bulk-substance review
FDA materials prepared for the July 2026 PCAC meeting describe its review of BPC-157 in the 503A bulk-substance process. They are background for committee discussion, not a product approval or final determination.
The FDA published briefing materials for the Pharmacy Compounding Advisory Committee meeting held July 23–24, 2026. Topics included BPC-157, KPV, TB-500, and MOTS-c in the context of potential 503A bulk-substance list evaluation.
According to the BPC-157 briefing document, FDA evaluated both the free-base and acetate forms in connection with prior nominations. The document provides background and questions for committee discussion; FDA states that a final determination will follow consideration of committee input and completion of its reviews.
The 503A process concerns the federal framework for drug compounding and is not FDA approval of a finished product. This update is a factual summary of official source material only and is not medical, legal, or regulatory advice.